KaloBios Pharmaceuticals, Inc. [KBIO] To Ring The NASDAQ Stock Market Closing Bell

ADVISORY, March 11, 2013 (GLOBE NEWSWIRE) --

What:

KaloBios Pharmaceuticals, Inc. [KBIO], a biopharmaceutical company dedicated to improving the lives of seriously ill patients with difficult-to-treat diseases through a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs), will visit the NASDAQ MarketSite in Times Square. 

In honor of the occasion, David Pritchard, President & CEO, will ring the Closing Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio

When:

Tuesday, March 12, 2013 – 3:45 p.m. to 4:00 p.m. ET   

Contact :

Joan E. Kureczka Kureczka/Martin Associates Tel: (415) 821-2413 Mobile:  (415) 690-0210 Joan@Kureczka-Martin.com

Consuelo Alatorre KaloBios Pharmaceuticals, Inc. Tel: (650) 243-3120 Mobile: (650) 278-6805 calatorre@kalobios.com

NASDAQ MarketSite:

Jen Knapp (212) 401-8916 Jennifer.knapp@nasdaqomx.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:

http://www.facebook.com/NASDAQ .        

For news tweets, please visit our Twitter page at:

http://twitter.com/nasdaqomx .

Webcast:

A live webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx .

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.                           

About KaloBios Pharmaceuticals, Inc. [KBIO]:

KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases.

Currently, KaloBios has three drug development programs:

  • KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, is being developed for the treatment of severe asthma and is currently enrolling patients in a 150 patient Phase 2 study in the United States, Europe and Australia.
  • KB001-A, an anti-PcrV mAb fragment, is partnered exclusively with Sanofi Pasteur and is being developed for the prevention and treatment of Pseudomonas aeruginosa ( Pa) infection. KaloBios has retained rights for the cystic fibrosis (CF) indication and has initiated a 180 patient Phase 2 study in CF subjects with chronic Pa infection in the United States. Sanofi is pursuing a ventilator associated pneumonia prevention indication in the intensive care setting.
  • KB004, an anti-EphA3 mAb, has potential in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in subjects with hematologic malignancies.

For more information on KaloBios Pharmaceuticals, please visit the web site at http://www.kalobios.com .

About NASDAQ OMX Group:

The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 26 markets including 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-55 microsecond average speeds with 99.99% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,300 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com . Follow us on Facebook ( http://www.facebook.com/NASDAQ ) and Twitter ( http://www.twitter.com/nasdaqomx ). (Symbol: NDAQ and member of S&P 500)

-NDAQA-